Advanced search
1 file | 299.50 KB Add to list

PEACE V - STORM randomized phase II trial for oligorecurrent nodal prostate cancer : acute toxicity

(2022) RADIOTHERAPY AND ONCOLOGY. 170(S1). p.S528-S529
Author
Organization

Downloads

  • (...).pdf
    • full text (Published version)
    • |
    • UGent only
    • |
    • PDF
    • |
    • 299.50 KB

Citation

Please use this url to cite or link to this publication:

MLA
Zilli, T., et al. “PEACE V - STORM Randomized Phase II Trial for Oligorecurrent Nodal Prostate Cancer : Acute Toxicity.” RADIOTHERAPY AND ONCOLOGY, vol. 170, no. S1, 2022, pp. S528–29.
APA
Zilli, T., Siva, S., Heikkila, R., Dirix, P., Liefhooghe, N., Otte, F., … Ost, P. (2022). PEACE V - STORM randomized phase II trial for oligorecurrent nodal prostate cancer : acute toxicity. RADIOTHERAPY AND ONCOLOGY, 170(S1), S528–S529.
Chicago author-date
Zilli, T., S. Siva, R. Heikkila, P. Dirix, N. Liefhooghe, F. Otte, A. Gomez-Iturriaga, et al. 2022. “PEACE V - STORM Randomized Phase II Trial for Oligorecurrent Nodal Prostate Cancer : Acute Toxicity.” In RADIOTHERAPY AND ONCOLOGY, 170:S528–29.
Chicago author-date (all authors)
Zilli, T., S. Siva, R. Heikkila, P. Dirix, N. Liefhooghe, F. Otte, A. Gomez-Iturriaga, W. Everaerts, M. Shelan, A. Conde-Moreno, F. Lopez Campos, A. Papachristofilou, M. Guckenberger, M. Scorsetti, A. Zapatero, A. Villafranca Iturre, C. Eito, F. Couñago, P. Muto, L. Van De Voorde, Valerie Fonteyne, D. Moon, K. Thon, C. Mercier, V. Achard, K. Stellamans, Els Goetghebeur, Dries Reynders, and Piet Ost. 2022. “PEACE V - STORM Randomized Phase II Trial for Oligorecurrent Nodal Prostate Cancer : Acute Toxicity.” In RADIOTHERAPY AND ONCOLOGY, 170:S528–S529.
Vancouver
1.
Zilli T, Siva S, Heikkila R, Dirix P, Liefhooghe N, Otte F, et al. PEACE V - STORM randomized phase II trial for oligorecurrent nodal prostate cancer : acute toxicity. In: RADIOTHERAPY AND ONCOLOGY. 2022. p. S528–9.
IEEE
[1]
T. Zilli et al., “PEACE V - STORM randomized phase II trial for oligorecurrent nodal prostate cancer : acute toxicity,” in RADIOTHERAPY AND ONCOLOGY, Copenhagen, Denmark, 2022, vol. 170, no. S1, pp. S528–S529.
@inproceedings{01GVM0SG5BHM10708BZ44G0R1Z,
  articleno    = {{OC-0603}},
  author       = {{Zilli, T. and  Siva, S. and  Heikkila, R. and  Dirix, P. and  Liefhooghe, N. and  Otte, F. and  Gomez-Iturriaga, A. and  Everaerts, W. and  Shelan, M. and  Conde-Moreno, A. and  Campos, F. Lopez and  Papachristofilou, A. and  Guckenberger, M. and  Scorsetti, M. and  Zapatero, A. and  Iturre, A. Villafranca and  Eito, C. and Couñago, F. and  Muto, P. and  Van De Voorde, L. and Fonteyne, Valerie and  Moon, D. and  Thon, K. and  Mercier, C. and  Achard, V. and  Stellamans, K. and Goetghebeur, Els and Reynders, Dries and Ost, Piet}},
  booktitle    = {{RADIOTHERAPY AND ONCOLOGY}},
  issn         = {{0167-8140}},
  language     = {{eng}},
  location     = {{Copenhagen, Denmark}},
  number       = {{S1}},
  pages        = {{OC-0603:S528--OC-0603:S529}},
  title        = {{PEACE V - STORM randomized phase II trial for oligorecurrent nodal prostate cancer : acute toxicity}},
  volume       = {{170}},
  year         = {{2022}},
}

Web of Science
Times cited: